Trilafon

Depression, Generalized Anxiety Disorder, Schizophrenia + 8 more

Treatment

12 FDA approvals

20 Active Studies for Trilafon

What is Trilafon

Perphenazine

The Generic name of this drug

Treatment Summary

A medication used to treat mental health disorders, similar to the effects of chlorpromazine.

Perphenazine

is the brand name

image of different drug pills on a surface

Trilafon Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Perphenazine

Perphenazine

1987

153

Approved as Treatment by the FDA

Perphenazine, also known as Perphenazine, is approved by the FDA for 12 uses like Anxiety and Generalized Anxiety Disorder .

Anxiety

Used to treat severe Anxiety in combination with Amitriptyline

Generalized Anxiety Disorder

Used to treat Anxiety in combination with Amitriptyline

Mental Depression

Used to treat moderate Depressed mood in combination with Amitriptyline

Depression

Used to treat Depression in combination with Amitriptyline

Mental Depression

Used to treat severe Depressed mood in combination with Amitriptyline

severe Nausea and vomiting

moderate Anxiety

Used to treat moderate Anxiety in combination with Amitriptyline

Schizophrenia

Helps manage Schizophrenia

Chronic Physical Illness

Used to treat Chronic Physical Illness in combination with Amitriptyline

Nausea

severe agitation

Used to treat severe agitation in combination with Amitriptyline

moderate Agitation

Used to treat moderate Agitation in combination with Amitriptyline

Effectiveness

How Trilafon Affects Patients

Perphenazine is a powerful medication used to treat psychiatric disorders. It belongs to a class of drugs called phenothiazines, which block the chemical dopamine in the brain. Perphenazine is 10-15 times stronger than other phenothiazine drugs and is just as effective as haloperidol in treating symptoms, but may cause similar early and late side effects.

How Trilafon works in the body

Perphenazine works by blocking the activity of dopamine receptors, which are responsible for sending signals to the vomiting center in the brain. It also binds to alpha-adrenergic receptors and stops them from sending messages that could lead to nausea and vomiting.

When to interrupt dosage

The prescribed measure of Trilafon is contingent upon the diagnosed ailment, including Generalized Anxiety Disorder, moderate Agitation and Depression. The amount of dosage is contingent upon the administration technique (e.g. Syrup - Oral or Tablet, sugar coated - Oral) outlined in the accompanying table.

Condition

Dosage

Administration

Depression

, 2.0 mg, 4.0 mg, 8.0 mg, 16.0 mg, 3.0 mg, 5.0 mg/mL, 2.0 mg/mL, 3.2 mg/mL, 16.0 mg/mL

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Liquid, Liquid - Oral, Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Syrup, Syrup - Oral

Nausea

, 2.0 mg, 4.0 mg, 8.0 mg, 16.0 mg, 3.0 mg, 5.0 mg/mL, 2.0 mg/mL, 3.2 mg/mL, 16.0 mg/mL

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Liquid, Liquid - Oral, Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Syrup, Syrup - Oral

Anxiety

, 2.0 mg, 4.0 mg, 8.0 mg, 16.0 mg, 3.0 mg, 5.0 mg/mL, 2.0 mg/mL, 3.2 mg/mL, 16.0 mg/mL

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Liquid, Liquid - Oral, Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Syrup, Syrup - Oral

Chronic Physical Illness

, 2.0 mg, 4.0 mg, 8.0 mg, 16.0 mg, 3.0 mg, 5.0 mg/mL, 2.0 mg/mL, 3.2 mg/mL, 16.0 mg/mL

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Liquid, Liquid - Oral, Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Syrup, Syrup - Oral

moderate Anxiety

, 2.0 mg, 4.0 mg, 8.0 mg, 16.0 mg, 3.0 mg, 5.0 mg/mL, 2.0 mg/mL, 3.2 mg/mL, 16.0 mg/mL

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Liquid, Liquid - Oral, Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Syrup, Syrup - Oral

moderate Agitation

, 2.0 mg, 4.0 mg, 8.0 mg, 16.0 mg, 3.0 mg, 5.0 mg/mL, 2.0 mg/mL, 3.2 mg/mL, 16.0 mg/mL

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Liquid, Liquid - Oral, Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Syrup, Syrup - Oral

Mental Depression

, 2.0 mg, 4.0 mg, 8.0 mg, 16.0 mg, 3.0 mg, 5.0 mg/mL, 2.0 mg/mL, 3.2 mg/mL, 16.0 mg/mL

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Liquid, Liquid - Oral, Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Syrup, Syrup - Oral

Mental Depression

, 2.0 mg, 4.0 mg, 8.0 mg, 16.0 mg, 3.0 mg, 5.0 mg/mL, 2.0 mg/mL, 3.2 mg/mL, 16.0 mg/mL

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Liquid, Liquid - Oral, Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Syrup, Syrup - Oral

Generalized Anxiety Disorder

, 2.0 mg, 4.0 mg, 8.0 mg, 16.0 mg, 3.0 mg, 5.0 mg/mL, 2.0 mg/mL, 3.2 mg/mL, 16.0 mg/mL

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Liquid, Liquid - Oral, Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Syrup, Syrup - Oral

Schizophrenia

, 2.0 mg, 4.0 mg, 8.0 mg, 16.0 mg, 3.0 mg, 5.0 mg/mL, 2.0 mg/mL, 3.2 mg/mL, 16.0 mg/mL

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Liquid, Liquid - Oral, Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Syrup, Syrup - Oral

severe agitation

, 2.0 mg, 4.0 mg, 8.0 mg, 16.0 mg, 3.0 mg, 5.0 mg/mL, 2.0 mg/mL, 3.2 mg/mL, 16.0 mg/mL

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Liquid, Liquid - Oral, Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Syrup, Syrup - Oral

Warnings

Trilafon Contraindications

Condition

Risk Level

Notes

large dose of CNS depressants

Do Not Combine

Brain Injuries

Do Not Combine

Liver Damage

Do Not Combine

Coma

Do Not Combine

Disease

Do Not Combine

greatly obtunded patients

Do Not Combine

Bone Marrow

Do Not Combine

There are 20 known major drug interactions with Trilafon.

Common Trilafon Drug Interactions

Drug Name

Risk Level

Description

Amisulpride

Major

Perphenazine may increase the antipsychotic activities of Amisulpride.

Astemizole

Major

The metabolism of Astemizole can be decreased when combined with Perphenazine.

Azelastine

Major

Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.

Dacomitinib

Major

The metabolism of Dacomitinib can be decreased when combined with Perphenazine.

Deutetrabenazine

Major

The risk or severity of adverse effects can be increased when Perphenazine is combined with Deutetrabenazine.

Trilafon Toxicity & Overdose Risk

Signs of an overdose of this drug include confusion and unconsciousness, and children may have seizures. It may take up to 48 hours for symptoms to become noticeable. Tests in rats and mice show that the lowest toxic dose is 318 mg/kg and 64 mg/kg, respectively.

image of a doctor in a lab doing drug, clinical research

Trilafon Novel Uses: Which Conditions Have a Clinical Trial Featuring Trilafon?

At present, 985 active clinical trials are investigating the potential of Trilafon to alleviate moderate Agitation, Anxiety and Nausea.

Condition

Clinical Trials

Trial Phases

Generalized Anxiety Disorder

181 Actively Recruiting

Not Applicable, Phase 2, Early Phase 1, Phase 4, Phase 1, Phase 3

Schizophrenia

97 Actively Recruiting

Phase 3, Not Applicable, Early Phase 1, Phase 4, Phase 1, Phase 2

moderate Anxiety

0 Actively Recruiting

Nausea

0 Actively Recruiting

Anxiety

0 Actively Recruiting

moderate Agitation

0 Actively Recruiting

Chronic Physical Illness

1 Actively Recruiting

Not Applicable

severe agitation

0 Actively Recruiting

Depression

304 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Early Phase 1, Phase 4, Phase 3

Mental Depression

0 Actively Recruiting

Mental Depression

0 Actively Recruiting

Trilafon Reviews: What are patients saying about Trilafon?

5

Patient Review

9/25/2009

Trilafon for Mental Disorder with Loss of Normal Personality & Reality

TARDIVE DYSKINESIA

5

Patient Review

3/24/2010

Trilafon for Schizophrenia

I've tried a lot of different antipsychotics, and this is the first one that's both effective and doesn't have too many side effects.

5

Patient Review

11/26/2010

Trilafon for Schizophrenia

I've tried other medications in the same class as Trilafon, and this one is by far the most effective with the least amount of side effects.

4.7

Patient Review

5/7/2010

Trilafon for Mental Disorder with Loss of Normal Personality & Reality

I have bipolar disorder, ADHD, and severe anxiety disorder. I've been on Trilafon for a little while now and it's really helped to stabilize my moods. Much better than any other medication I've tried in the past.

4.7

Patient Review

4/10/2010

Trilafon for Mental Disorder with Loss of Normal Personality & Reality

I initially forgot to take this medication, but I was really pleased with how it curbed my appetite. I didn't feel the need to overeat anymore.

4

Patient Review

7/14/2010

Trilafon for Schizophrenia

I felt more focused and energetic, with fewer racing thoughts.

4

Patient Review

6/2/2009

Trilafon for Schizophrenia

3.7

Patient Review

5/14/2013

Trilafon for Schizophrenia

This medication was highly effective at removing my positive symptoms of schizophrenia. However, I developed abnormal mouth and tongue movements as a result. These movements have continued even after going off the medication, which has been since January. Therefore, I would not recommend this drug to anyone.

2.3

Patient Review

9/29/2012

Trilafon for Mental Disorder with Loss of Normal Personality & Reality

I was prescribed this medication after being misdiagnosed while in foster care. Even though it's been three years since I stopped taking the medicine, I continue to suffer from a variety of side effects, including sun sensitivity, irregular periods, an irregular heartbeat, sexual problems and eye twitches.

1

Patient Review

2/15/2012

Trilafon for Mental Disorder with Loss of Normal Personality & Reality

This treatment made me feel really out of it and not in a good way.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about trilafon

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What does perphenazine do to your brain?

"Perphenazine is a type of medication known as a conventional antipsychotic. It works by reducing abnormal excitement in the brain."

Answered by AI

How long does it take for Trilafon to work?

"It may take as much as 4-6 weeks of regular use to see the full benefit of the medication, even though you may notice some effects soon after starting."

Answered by AI

Is Trilafon still available?

"The drug Trilafon is no longer being manufactured in the United States, but similar drugs may still be available. Trilafon was an antipsychotic drug used to treat schizophrenia. It belonged to a class of drugs called phenothiazines."

Answered by AI

What is Trilafon used for?

"Aripiprazole works by helping to restore the balance of certain natural substances (neurotransmitters) in the brain.

Aripiprazole is a medication used to treat certain mental disorders such as schizophrenia and bipolar disorder. This medicine helps the patient to think more clearly and take part in everyday life. It can reduce aggressive behavior and the desire to hurt oneself or others. Aripiprazole works by restoring the balance of certain neurotransmitters in the brain."

Answered by AI

Clinical Trials for Trilafon

Have you considered Trilafon clinical trials?

We made a collection of clinical trials featuring Trilafon, we think they might fit your search criteria.
Go to Trials
Image of Western Psychiatric Hospital/University of Pittsburgh in Pittsburgh, United States.

Sleep and Circadian Interventions for Suicide

18 - 25
All Sexes
Pittsburgh, PA

The purpose of this study is to examine the extent to which delivering sleep and circadian focused interventions in addition to evidenced based psychiatric care for depression and suicide risk may contribute to decreasing suicide risk among high risk young adults. Investigators will evaluate three interventions targeting sleep in acutely suicidal college students enrolled in intensive outpatient treatment. Participants will be randomly assigned to one of three intervention groups: 1. Triple Chronotherapy (TCT)+ Transdiagnostic Sleep and Circadian Intervention (TSC) 2. Transdiagnostic Sleep and Circadian Intervention (TSC) 3. Sleep Feedback (SF) Participants will be followed for 6 months with primary outcome domains of suicidal thoughts and behaviors and depression evaluated by blinded clinicians at short (Days 1-4 of intervention), medium (2 months) and long (6 month) term intervals.

Waitlist Available
Has No Placebo

Western Psychiatric Hospital/University of Pittsburgh

Tina Goldstein, PhD

Image of University of South Florida in Tampa, United States.

WeACT Program for Caregivers of People With Dementia

18+
All Sexes
Tampa, FL

The goal of this clinical trial is to learn whether WeACT, a self-paced, web-based program, is feasible and helpful for adult family caregivers of a relative living with dementia. WeACT is based on acceptance and commitment therapy (ACT), which teaches skills to handle difficult thoughts and feelings and take steps toward what matters most. The main questions this study aims to answer are: * Can caregivers complete WeACT as planned? * Do caregivers show improvements in mental health and coping after using WeACT? * What are caregivers' experiences with the program, and what suggestions do they have to improve it? Participants will: * Complete six self-paced weekly online modules and use the daily practice section during the program. * Complete online questionnaires before starting and after completing the program. * Take part in one online interview about their experience.

Waitlist Available
Has No Placebo

University of South Florida

Areum Han

Image of Fred Hutch/University of Washington Cancer Consortium in Seattle, United States.

Psilocybin Therapy for Anxiety and Depression in Cancer

18 - 85
All Sexes
Seattle, WA

This phase II trial tests the safety, side effects and how well group retreat psilocybin therapy works for the treatment of anxiety and depression in patients with solid tumors that have spread from where they first started (primary site) to other places in the body (metastatic) or with hematologic cancers for which no treatment is currently available (incurable). For patients with metastatic, incurable cancer, unrelieved anxiety and existential distress can cause profound suffering. Psilocybin therapy can relieve anxiety and existential distress by disrupting patterns of thinking that contribute to anxiety and depression. Psilocybin is a substance being studied in the treatment of anxiety or depression in patients with cancer. In this study, a pharmaceutical grade of psilocybin will be used that has been approved by the FDA for research, provided by Filament Health. Psilocybin acts on the brain by resetting the brain's activity and increasing connections between brain regions, particularly those involved in mood regulation and self-perception. In this study psilocybin is combined with structured discussions and reflections that enable patients to have new insights about their situation. In a prior study, group retreat psilocybin therapy was proven to be safe and this study tests a refined dosing regimen for symptoms of anxiety and depression in patients with metastatic solid tumors or incurable hematologic malignancies.

Phase 2
Waitlist Available

Fred Hutch/University of Washington Cancer Consortium

Anthony Back, MD

Image of Wahwala Iyohlogya/Peaceful Means in Pine Ridge, United States.

Lakota Family Acceptance Program for Depression and Anxiety

Any Age
All Sexes
Pine Ridge, SD

The goal of this open pilot trial (OPT) is to develop a Lakota-adapted Family Acceptance Project (LFAP) for Indigenous 2SLGBTQ+ youth and their caregivers. The OPT is specifically focused on acceptability, feasibility, and safety of programming and research protocols. The investigators will also examine pre- to post- changes on outcomes for the sole purposes of making sure scores on measures are changing in the hypothesized direction (e.g., depression scores are going from moderate to minimal as opposed to no change or depression scores increasing). Once enrolled in the study, participants complete a baseline survey. Then participants will engage in LFAP which is an 8-session group intervention; sessions will be scheduled once a week for eight weeks (at 2 hours per session). Participants will complete survey instruments before and immediately after the program sessions, in addition to post-program surveys and an exit interview.

Recruiting
Has No Placebo

Wahwala Iyohlogya/Peaceful Means (+1 Sites)

Katie Edwards, PhD

Have you considered Trilafon clinical trials?

We made a collection of clinical trials featuring Trilafon, we think they might fit your search criteria.
Go to Trials
Image of Seaway Valley Community Health Centre (Cardiac Rehab Program) in Cornwall, Canada.

FRAME for Heart Failure

18+
All Sexes
Cornwall, Canada

Heart failure is a high-risk, chronic condition that impacts patients' mental health. Approximately 50% of heart failure patients experience comorbid mental health conditions, such as stress, depression and anxiety, which affect their day-to-day lives. Despite this interconnection, the integration of mental health awareness and support into cardiac care remains limited. To address this gap, the FRAME (Foundation, Recognition, Awareness, Management, Engagement) intervention was co-designed by researchers, healthcare providers, health system decisionmakers, and patient partners. This pilot study evaluates the feasibility of implementing the FRAME intervention in pilot clinical sites within two health regions in Ontario, Canada, including team-based family medicine clinics, cardiac rehabilitation/specialist clinics, and emergency departments. Utilizing a pretest-posttest hybrid 1 model intervention design, this study evaluates process indicators and patient-focused outcomes through surveys and semi-structured qualitative interviews. Findings from this study will inform a future large scale cohort study and scalable integration of the FRAME tool into existing cardiac care pathways to enhance mental health awareness and support among heart failure patients.

Recruiting
Has No Placebo

Seaway Valley Community Health Centre (Cardiac Rehab Program) (+8 Sites)

Image of Fort Bend ISD in Sugar Land, United States.

Wellbeing Interventions for Anxiety

10 - 20
All Sexes
Sugar Land, TX

The goal of this clinical trial is to learn if psychology and music based interventions can impact anxiety and overall wellbeing in adolescents enrolled in choral music classes. The main questions it aims to answer are: Do specific psychology and music based breathing interventions impact anxiety and overall wellbeing in adolescents? Do specific psychology and music based performance anxiety reduction interventions impact anxiety and overall wellbeing in adolescents? Do specific psychology and music based emotion regulation interventions impact anxiety and overall wellbeing in adolescents? Researchers will compare results of pre-test data, post-test data, qualitative interviews, and surveys of adult choral directors to see if there is a measurable impact on adolescent anxiety and overall wellbeing. Participants will: * Use box breathing during choral music warm-ups to connect choral breathing to breathing for anxiety reduction * Use "magnify" technique to compare cognitive distortions regarding an upcoming performance that may cause anxiety to the most likely realistic outcome * Use emotion regulation through song lyrics technique to connect lyrics of choral music repertoire to participants experienced emotions

Waitlist Available
Has No Placebo

Fort Bend ISD

Jane Kuehne, PhD

Have you considered Trilafon clinical trials?

We made a collection of clinical trials featuring Trilafon, we think they might fit your search criteria.
Go to Trials